-
Professor Qinlong Zheng: Focusing on Clonal Evolution to Optimize Hematologic Malignancy Diagnosis and Treatment
To further advance scientific research and clinical practice in hematologic malignancies in China and establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing…
-
Professor Gao Zifen: Breakthroughs and Future Directions in Hematologic Malignancy Diagnostics — From Integrated to Precision Medicine | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference
To further advance scientific research and clinical practice in hematologic malignancies in China and to establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the…
-
Professor Wu Tong: Exploring the “Gaobo Model” of Hematopoietic Stem Cell Transplantation Strategies | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference
To further advance both scientific research and clinical practice in hematologic malignancies in China and to establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and…
-
Professor Tong Chunrong: Entering a New Era of Integrated and Precision Diagnosis and Treatment in Hematologic Malignancies | 2026 Boren Precision Hematologic Oncology Conference
To further advance scientific research and clinical practice in hematologic malignancies in China and to establish a high-level academic exchange platform, the 2026 Boren Precision Hematologic Oncology Conference officially opened in Beijing on May 16 in a hybrid online-offline format. The conference was jointly hosted by the Beijing Association for the Promotion of Integrated Traditional…
-
“PI Perspectives” S01E01 | Opening Episode: The HOPE Series Panorama — A Chinese Bladder-Preservation Strategy from Chemo-Immunotherapy to ADCs
The purpose behind launching this series is very clear: more and more original, high-quality clinical studies are emerging from China, and we hope to amplify their voices—not only domestically, but also internationally through our platform for global academic exchange and communication.
-
PI Insights S01E02 | Where Are the Boundaries of Bladder Preservation? — The Clinical Rationale and Technical Foundation Behind the Expanded Enrollment Criteria of HOPE-02/03
In the previous episode, we reviewed the full evolution of the HOPE series from HOPE-01 through HOPE-04. Among all its design features, one detail may represent the most distinctive — and perhaps boldest — aspect of the HOPE program within the global bladder-preservation landscape: its enrollment criteria.
-
PI Perspectives S01E03 | Finding Balance in the Chemo-Immunotherapy Era — A Strategic Dialogue Between HOPE-02, NIAGARA, RETAIN-02, and INDI-BLADE
In the previous episode, we explored the clinical rationale and technical safeguards behind the expanded enrollment criteria of HOPE-02/03. In this installment, we place HOPE-02 within the broader landscape of perioperative and bladder-preservation research in muscle-invasive bladder cancer (MIBC) to better understand its position among contemporary global studies.
-
Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma
On April 21, 2026, Professor Shi Yanxia and Professor An Xin’s team from Sun Yat-sen University Cancer Center published their latest findings in the international journal Cancer Communications under the title “Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.”
Connecting Medical Expertise through Media